Kidney Transplantation Under FK 506
- 4 July 1990
- journal article
- research article
- Published by American Medical Association (AMA) in Jama-Journal Of The American Medical Association
- Vol. 264 (1), 63-67
- https://doi.org/10.1001/jama.1990.03450010067032
Abstract
The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13 months, all but 2 of the 36 patients are alive, 29 (81%) are dialysis free, and most have good renal function. Twenty of the 29 dialysis-free patients are receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney was lost to cellular rejection. However, patients who had antidonor cytotoxic antibodies in current or historical serum samples had a high rate (3 of 9) of irreversible humoral rejection. A low incidence of posttransplant hypertension was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum cholesterol levels in patients who took FK 506 were unexpectedly low, and the effect on the level of uric acid was minimal. The side effects of FK 506 therapy include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. These are similar to the side effects of cyclosporine use, but probably less severe. The seeming safety, efficacy, and relative freedom from side effects of FK 506 encourage further trials in kidney transplantation. (JAMA. 1990;264:63-67)This publication has 37 references indexed in Scilit:
- IN VITRO EFFECTS OF FK-506 ON HUMAN AND RAT ISLETSTransplantation, 1990
- FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhoodThe Lancet, 1990
- IMPROVED GRAFT SURVIVAL FOR FLOW CYTOMETRY AND ANTIHUMAN GLOBULIN CROSSMATCH-NEGATIVE RETRANSPLANT RECIPIENTSTransplantation, 1990
- CyclosporineNew England Journal of Medicine, 1989
- CHARACTERIZATION OF LYMPHOCYTOTOXIC ANTIBODIES CAUSING A POSITIVE CROSSMATCH IN RENAL TRANSPLANTATIONTransplantation, 1989
- A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomeraseNature, 1989
- A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilinNature, 1989
- Cyclosporine-Induced Hyperuricemia and GoutNew England Journal of Medicine, 1989
- FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.The Journal of Antibiotics, 1987
- FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.The Journal of Antibiotics, 1987